



## Clinical trial results:

**Effisayil™ 1: Multi-center, double-blind, randomized, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of a single intravenous dose of spesolimab (BI 655130) in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity**

### Summary

|                          |                 |
|--------------------------|-----------------|
| EudraCT number           | 2017-004231-37  |
| Trial protocol           | FR DE           |
| Global end of trial date | 05 January 2021 |

### Results information

|                                |                 |
|--------------------------------|-----------------|
| Result version number          | v1              |
| This version publication date  | 11 January 2022 |
| First version publication date | 11 January 2022 |

### Trial information

#### Trial identification

|                       |           |
|-----------------------|-----------|
| Sponsor protocol code | 1368-0013 |
|-----------------------|-----------|

#### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT03782792 |
| WHO universal trial number (UTN)   | -           |

Notes:

### Sponsors

|                              |                                                                                                                                                                                  |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sponsor organisation name    | Boehringer Ingelheim                                                                                                                                                             |
| Sponsor organisation address | Binger Strasse 173, Ingelheim am Rhein, Germany, 55216                                                                                                                           |
| Public contact               | Boehringer Ingelheim, Call Center, Boehringer Ingelheim, 001 18002430127, <a href="mailto:clintrriage.rdg@boehringer-ingelheim.com">clintrriage.rdg@boehringer-ingelheim.com</a> |
| Scientific contact           | Boehringer Ingelheim, Call Center, Boehringer Ingelheim, 001 18002430127, <a href="mailto:clintrriage.rdg@boehringer-ingelheim.com">clintrriage.rdg@boehringer-ingelheim.com</a> |

Notes:

### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |                   |
|------------------------------------------------------|-------------------|
| Analysis stage                                       | Final             |
| Date of interim/final analysis                       | 01 April 2021     |
| Is this the analysis of the primary completion data? | Yes               |
| Primary completion date                              | 23 September 2020 |
| Global end of trial reached?                         | Yes               |
| Global end of trial date                             | 05 January 2021   |
| Was the trial ended prematurely?                     | No                |

Notes:

## General information about the trial

Main objective of the trial:

To evaluate efficacy, tolerability, and safety of spesolimab (BI 655130) compared with placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.

Protection of trial subjects:

Week1/Day 2 to D7:

- If the severity and progression of the disease worsened within the 1st week and required immediate treatment, then the investigator could treat the patient with the escape medication of his/her choice.

After Day 8:

- Patients who did not achieve a clinical response (Generalized Pustular Psoriasis Physician Global Assessment 0 or 1) but had disease worsening subsequent to Day 8 could receive an escape treatment chosen by the investigator

- Patients who achieved a clinical response and later had disease worsening that was not severe enough to meet the criteria for recurrence for Generalized Pustular Psoriasis (GPP) flare could receive the escape medication. However, it was recommended to wait until the patient met the criteria for recurrence of GPP flare since there was an option to administer rescue medication with Open Label spesolimab instead at this time.

Patients were allowed to withdraw their consent at any time without the need to justify the decision.

Background therapy: -

Evidence for comparator: -

|                                                           |                  |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment                          | 20 February 2019 |
| Long term follow-up planned                               | Yes              |
| Long term follow-up rationale                             | Safety, Efficacy |
| Long term follow-up duration                              | 5 Years          |
| Independent data monitoring committee (IDMC) involvement? | Yes              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                       |
|--------------------------------------|-----------------------|
| Country: Number of subjects enrolled | China: 9              |
| Country: Number of subjects enrolled | France: 18            |
| Country: Number of subjects enrolled | Germany: 6            |
| Country: Number of subjects enrolled | Japan: 7              |
| Country: Number of subjects enrolled | Korea, Republic of: 1 |
| Country: Number of subjects enrolled | Malaysia: 20          |
| Country: Number of subjects enrolled | Singapore: 1          |
| Country: Number of subjects enrolled | Switzerland: 1        |
| Country: Number of subjects enrolled | Taiwan: 7             |
| Country: Number of subjects enrolled | Thailand: 1           |

|                                      |                  |
|--------------------------------------|------------------|
| Country: Number of subjects enrolled | Tunisia: 9       |
| Country: Number of subjects enrolled | United States: 5 |
| Worldwide total number of subjects   | 85               |
| EEA total number of subjects         | 24               |

Notes:

| <b>Subjects enrolled per age group</b>    |    |
|-------------------------------------------|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 0  |
| Children (2-11 years)                     | 0  |
| Adolescents (12-17 years)                 | 0  |
| Adults (18-64 years)                      | 79 |
| From 65 to 84 years                       | 6  |
| 85 years and over                         | 0  |

## Subject disposition

### Recruitment

Recruitment details:

This was a randomized, placebo-controlled, double-blind, parallel-group, single-dose trial with 2 treatment groups (spesolimab and placebo) in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.

### Pre-assignment

Screening details:

All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Double blind                   |
| Roles blinded                | Subject, Investigator          |

Blinding implementation details:

Patients and investigators involved in the trial conduct remained blinded with regard to the randomized treatment assignments until after database lock for the final trial analysis.

### Arms

|                              |         |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes     |
| Arm title                    | Placebo |

Arm description:

Patients received intravenously (i.v.) solution for infusion containing 0 mg of placebo to spesolimab on Day 1 (D1) of Week 1 (Wk1). If the severity and progression of the disease worsened within the first week the investigator could treat the patient with a Standard of Care (SoC) treatment of his/her choice (escape medication). If the disease condition was stable, it was recommended to wait until the primary endpoint visit (Wk1/D8) before prescribing an escape medication (SoC) since there was an option to administer open label (OL) spesolimab instead at this time. If escape medication was administered within the first week, the patient was not eligible to receive treatment with a single OL i.v. dose of 900 mg spesolimab on D8. If the condition of the patients worsened after Wk1/D8 patients were eligible to receive rescue treatment with open label spesolimab (only one single rescue i.v. dose of 900 mg spesolimab) after Wk1 to Wk 12.

|                                        |                       |
|----------------------------------------|-----------------------|
| Arm type                               | Placebo               |
| Investigational medicinal product name | Placebo               |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Patients received intravenously (i.v.) solution for infusion containing 0 mg of placebo to spesolimab on Day 1 (D1) of Week 1 (Wk1).

|           |                          |
|-----------|--------------------------|
| Arm title | Spesolimab 900 mg i.v SD |
|-----------|--------------------------|

Arm description:

Patients received intravenously (i.v.) a single dose (SD) of solution for infusion containing 900 milligram (mg) of spesolimab on Day 1 (D1) of Week 1 (Wk1). If the severity and progression of the disease worsened within the first week the investigator could treat the patient with a Standard of Care (SoC) treatment of his/her choice (escape medication). If the disease condition was stable, it was recommended to wait until the primary endpoint visit (Wk1/D8) before prescribing an escape medication (SoC) since there was an option to administer open label (OL) spesolimab instead at this time. If escape medication was administered within the first week, the patient was not eligible to receive treatment with a single OL i.v. dose of 900 mg spesolimab on D8. If the condition of the patients worsened after Wk1/D8 patients were eligible to receive rescue treatment with open label spesolimab (only one single

rescue i.v. dose of 900 mg spesolimab) after Wk1 to Wk 12.

|                                        |                       |
|----------------------------------------|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | Spesolimab            |
| Investigational medicinal product code |                       |
| Other name                             | BI 655130             |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Patients received intravenously (i.v.) a single dose (SD) of solution for infusion containing 900 milligram (mg) of spesolimab on Day 1 (D1) of Week 1 (Wk1).

| <b>Number of subjects in period 1<sup>[1]</sup></b> | Placebo           | Spesolimab 900 mg i.v SD |
|-----------------------------------------------------|-------------------|--------------------------|
| Started                                             | 18                | 35                       |
| Received OL Spesolimab at Wk1/D8                    | 15 <sup>[2]</sup> | 12 <sup>[3]</sup>        |
| Received rescue Spesolimab after Wk1                | 2 <sup>[4]</sup>  | 4 <sup>[5]</sup>         |
| Completed                                           | 17                | 32                       |
| Not completed                                       | 1                 | 3                        |
| Consent withdrawn by subject                        | 1                 | 2                        |
| Patient left the country                            | -                 | 1                        |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Out of 85 enrolled subjects only 53 were randomized.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Out of 18 subjects that were treated with Placebo at Day 1 only 15 received Open Label Spesolimab at Week 1/Day 8.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Out of 35 subjects that were treated with Spesolimab at Day 1 only 12 received Open Label Spesolimab at Week 1/Day 8.

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Out of 18 subjects that were treated with Placebo at Day 1 only 2 received received rescue Spesolimab after Week 1.

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Out of 35 subjects that were treated with Spesolimab at Day 1 only 4 received received rescue Spesolimab after Week 1.

## Baseline characteristics

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Patients received intravenously (i.v.) solution for infusion containing 0 mg of placebo to spesolimab on Day 1 (D1) of Week 1 (Wk1). If the severity and progression of the disease worsened within the first week the investigator could treat the patient with a Standard of Care (SoC) treatment of his/her choice (escape medication). If the disease condition was stable, it was recommended to wait until the primary endpoint visit (Wk1/D8) before prescribing an escape medication (SoC) since there was an option to administer open label (OL) spesolimab instead at this time. If escape medication was administered within the first week, the patient was not eligible to receive treatment with a single OL i.v. dose of 900 mg spesolimab on D8. If the condition of the patients worsened after Wk1/D8 patients were eligible to receive rescue treatment with open label spesolimab (only one single rescue i.v. dose of 900 mg spesolimab) after Wk1 to Wk 12.

|                       |                          |
|-----------------------|--------------------------|
| Reporting group title | Spesolimab 900 mg i.v SD |
|-----------------------|--------------------------|

Reporting group description:

Patients received intravenously (i.v.) a single dose (SD) of solution for infusion containing 900 milligram (mg) of spesolimab on Day 1 (D1) of Week 1 (Wk1). If the severity and progression of the disease worsened within the first week the investigator could treat the patient with a Standard of Care (SoC) treatment of his/her choice (escape medication). If the disease condition was stable, it was recommended to wait until the primary endpoint visit (Wk1/D8) before prescribing an escape medication (SoC) since there was an option to administer open label (OL) spesolimab instead at this time. If escape medication was administered within the first week, the patient was not eligible to receive treatment with a single OL i.v. dose of 900 mg spesolimab on D8. If the condition of the patients worsened after Wk1/D8 patients were eligible to receive rescue treatment with open label spesolimab (only one single rescue i.v. dose of 900 mg spesolimab) after Wk1 to Wk 12.

| Reporting group values                                                  | Placebo | Spesolimab 900 mg i.v SD | Total |
|-------------------------------------------------------------------------|---------|--------------------------|-------|
| Number of subjects                                                      | 18      | 35                       | 53    |
| Age categorical                                                         |         |                          |       |
| Randomized Set (RS): This patient set included all randomized patients. |         |                          |       |
| Units: Subjects                                                         |         |                          |       |
| In utero                                                                | 0       | 0                        | 0     |
| Preterm newborn infants (gestational age < 37 wks)                      | 0       | 0                        | 0     |
| Newborns (0-27 days)                                                    | 0       | 0                        | 0     |
| Infants and toddlers (28 days-23 months)                                | 0       | 0                        | 0     |
| Children (2-11 years)                                                   | 0       | 0                        | 0     |
| Adolescents (12-17 years)                                               | 0       | 0                        | 0     |
| Adults (18-64 years)                                                    | 18      | 33                       | 51    |
| From 65-84 years                                                        | 0       | 2                        | 2     |
| 85 years and over                                                       | 0       | 0                        | 0     |
| Age Continuous                                                          |         |                          |       |
| Randomized Set (RS): This patient set included all randomized patients. |         |                          |       |
| Units: years                                                            |         |                          |       |
| arithmetic mean                                                         | 42.6    | 43.2                     |       |
| standard deviation                                                      | ± 8.4   | ± 12.1                   | -     |
| Sex: Female, Male                                                       |         |                          |       |
| Randomized Set (RS): This patient set included all randomized patients. |         |                          |       |
| Units: Participants                                                     |         |                          |       |
| Female                                                                  | 15      | 21                       | 36    |
| Male                                                                    | 3       | 14                       | 17    |

|                                                                         |    |    |    |
|-------------------------------------------------------------------------|----|----|----|
| Race (NIH/OMB)                                                          |    |    |    |
| Randomized Set (RS): This patient set included all randomized patients. |    |    |    |
| Units: Subjects                                                         |    |    |    |
| American Indian or Alaska Native                                        | 0  | 0  | 0  |
| Asian                                                                   | 13 | 16 | 29 |
| Native Hawaiian or Other Pacific Islander                               | 0  | 0  | 0  |
| Black or African American                                               | 0  | 0  | 0  |
| White                                                                   | 5  | 19 | 24 |
| More than one race                                                      | 0  | 0  | 0  |
| Unknown or Not Reported                                                 | 0  | 0  | 0  |
| Ethnicity (NIH/OMB)                                                     |    |    |    |
| Randomized Set (RS): This patient set included all randomized patients. |    |    |    |
| Units: Subjects                                                         |    |    |    |
| Hispanic or Latino                                                      | 0  | 0  | 0  |
| Not Hispanic or Latino                                                  | 18 | 35 | 53 |
| Unknown or Not Reported                                                 | 0  | 0  | 0  |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Placebo                  |
| Reporting group description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                          |
| Patients received intravenously (i.v.) solution for infusion containing 0 mg of placebo to spesolimab on Day 1 (D1) of Week 1 (Wk1). If the severity and progression of the disease worsened within the first week the investigator could treat the patient with a Standard of Care (SoC) treatment of his/her choice (escape medication). If the disease condition was stable, it was recommended to wait until the primary endpoint visit (Wk1/D8) before prescribing an escape medication (SoC) since there was an option to administer open label (OL) spesolimab instead at this time. If escape medication was administered within the first week, the patient was not eligible to receive treatment with a single OL i.v. dose of 900 mg spesolimab on D8. If the condition of the patients worsened after Wk1/D8 patients were eligible to receive rescue treatment with open label spesolimab (only one single rescue i.v. dose of 900 mg spesolimab) after Wk1 to Wk 12.                          |                          |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Spesolimab 900 mg i.v SD |
| Reporting group description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                          |
| Patients received intravenously (i.v.) a single dose (SD) of solution for infusion containing 900 milligram (mg) of spesolimab on Day 1 (D1) of Week 1 (Wk1). If the severity and progression of the disease worsened within the first week the investigator could treat the patient with a Standard of Care (SoC) treatment of his/her choice (escape medication). If the disease condition was stable, it was recommended to wait until the primary endpoint visit (Wk1/D8) before prescribing an escape medication (SoC) since there was an option to administer open label (OL) spesolimab instead at this time. If escape medication was administered within the first week, the patient was not eligible to receive treatment with a single OL i.v. dose of 900 mg spesolimab on D8. If the condition of the patients worsened after Wk1/D8 patients were eligible to receive rescue treatment with open label spesolimab (only one single rescue i.v. dose of 900 mg spesolimab) after Wk1 to Wk 12. |                          |

### Primary: Proportion of patients with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 indicating no visible pustules at Week 1

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Proportion of patients with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 indicating no visible pustules at Week 1 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                     |
| The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) relies on clinical assessment of the Generalized Pustular Psoriasis (GPP) patient's skin presentation. The investigator (or qualified site personnel) scored the erythema, pustules, and scaling of all GPP lesions from 0 to 4.<br>The GPPGA pustulation subscore ranges from 0 to 4 where:<br>0 = clear;<br>1 = almost clear;<br>2 = mild;<br>3 = moderate;<br>4 = severe.<br>A lower GPPGA pustulation subscore indicates a better outcome. A GPPGA pustulation subscore of 0 means no visible pustules.<br>The proportion of patients who achieved a GPPGA pustulation subscore of 0 at Week 1 is reported.<br>Randomized Set (RS) (via estimand EN-NRI): EN = Any assessments after death, or any use of escape medication due to disease worsening prior to Week 1 were considered to represent a non-response. NRI = Non-response imputation for any missing data. |                                                                                                                                                                     |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Primary                                                                                                                                                             |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                     |
| At Week 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                     |



| End point values                  | Placebo                | Spesolimab 900 mg i.v SD |  |  |
|-----------------------------------|------------------------|--------------------------|--|--|
| Subject group type                | Reporting group        | Reporting group          |  |  |
| Number of subjects analysed       | 18 <sup>[1]</sup>      | 35 <sup>[2]</sup>        |  |  |
| Units: Proportion of participants |                        |                          |  |  |
| number (confidence interval 95%)  | 0.056 (0.010 to 0.258) | 0.543 (0.382 to 0.695)   |  |  |

Notes:

[1] - RS via estimand EN-NRI

[2] - RS via estimand EN-NRI

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                             | Statistical Analysis 1             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                      |                                    |
| The Suissa-Shuster Z-pooled test was implemented to test the treatment effect on the primary endpoint on the RS (estimand EN) at a 1-sided, alpha level of 0.025. Confidence intervals (95%) around the risk difference were produced using the Chan and Zhang method. |                                    |
| Comparison groups                                                                                                                                                                                                                                                      | Placebo v Spesolimab 900 mg i.v SD |
| Number of subjects included in analysis                                                                                                                                                                                                                                | 53                                 |
| Analysis specification                                                                                                                                                                                                                                                 | Pre-specified                      |
| Analysis type                                                                                                                                                                                                                                                          |                                    |
| P-value                                                                                                                                                                                                                                                                | = 0.0004 <sup>[3]</sup>            |
| Method                                                                                                                                                                                                                                                                 | Suissa-Shuster Z-pooled test       |
| Parameter estimate                                                                                                                                                                                                                                                     | Risk difference (RD)               |
| Point estimate                                                                                                                                                                                                                                                         | 0.487                              |
| Confidence interval                                                                                                                                                                                                                                                    |                                    |
| level                                                                                                                                                                                                                                                                  | 95 %                               |
| sides                                                                                                                                                                                                                                                                  | 2-sided                            |
| lower limit                                                                                                                                                                                                                                                            | 0.215                              |
| upper limit                                                                                                                                                                                                                                                            | 0.672                              |

Notes:

[3] - One-sided P Value.

## Secondary: Key secondary: Proportion of patients with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1 at Week 1

|                 |                                                                                                                                           |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Key secondary: Proportion of patients with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1 at Week 1 |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

GPPGA relied on clinical assessment of the Generalized Pustular Psoriasis (GPP) patient's skin presentation. The GPPGA total score was calculated by taking the mean of the erythema subscore, pustules subscore and scaling/crusting subscore. The severity of each subscore was assessed using a 5 point scale score ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). The final GPPGA score is assigned as follows:

- 0, if scores for all three subscores are 0,
- 1, if  $0 < \text{mean} < 1.5$ ,
- 2, if  $1.5 \leq \text{mean} < 2.5$ ,
- 3, if  $2.5 \leq \text{mean} < 3.5$ ,
- 4, if  $\text{mean} \geq 3.5$ .

A lower GPPGA score indicates a better outcome, with 0 being clear and 1 being almost clear. The proportion of patients with a GPPGA score of 0 or 1 at Week 1 is reported.

Randomized Set (RS) (via estimand EN-NRI): EN = Any assessments after death, or any use of escape medication due to disease worsening prior to Week 1 were considered to represent a non-response. NRI = Non-response imputation for any missing data.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Week 1.

| End point values                  | Placebo                | Spesolimab 900 mg i.v SD |  |  |
|-----------------------------------|------------------------|--------------------------|--|--|
| Subject group type                | Reporting group        | Reporting group          |  |  |
| Number of subjects analysed       | 18 <sup>[4]</sup>      | 35 <sup>[5]</sup>        |  |  |
| Units: Proportion of participants |                        |                          |  |  |
| number (confidence interval 95%)  | 0.111 (0.031 to 0.328) | 0.429 (0.280 to 0.591)   |  |  |

Notes:

[4] - RS via estimand EN-NRI

[5] - RS via estimand EN-NRI

## Statistical analyses

| Statistical analysis title | Statistical Analysis 2 |
|----------------------------|------------------------|
|----------------------------|------------------------|

Statistical analysis description:

The Suissa-Shuster Z-pooled test was implemented to test the treatment effect on the RS (estimand EN) at a 1-sided, alpha level of 0.025. Confidence intervals (95%) around the risk difference were produced using the Chan and Zhang method.

|                                         |                                    |
|-----------------------------------------|------------------------------------|
| Comparison groups                       | Placebo v Spesolimab 900 mg i.v SD |
| Number of subjects included in analysis | 53                                 |
| Analysis specification                  | Pre-specified                      |
| Analysis type                           |                                    |
| P-value                                 | = 0.0118 <sup>[6]</sup>            |
| Method                                  | Suissa-Shuster Z-pooled test       |
| Parameter estimate                      | Risk difference (RD)               |
| Point estimate                          | 0.317                              |
| Confidence interval                     |                                    |
| level                                   | 95 %                               |
| sides                                   | 2-sided                            |
| lower limit                             | 0.022                              |
| upper limit                             | 0.527                              |

Notes:

[6] - One-sided P Value.

## Secondary: Proportion of patients with a Psoriasis Area and Severity Index for Generalized Pustular Psoriasis (GPPASI) 75 at Week 4

|                 |                                                                                                                          |
|-----------------|--------------------------------------------------------------------------------------------------------------------------|
| End point title | Proportion of patients with a Psoriasis Area and Severity Index for Generalized Pustular Psoriasis (GPPASI) 75 at Week 4 |
|-----------------|--------------------------------------------------------------------------------------------------------------------------|

End point description:

Generalized Pustular Psoriasis Area and Severity Index (GPPASI) provides a numeric scoring for a patient's overall Generalized Pustular Psoriasis (GPP) disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin affected by erythema, pustules, and scaling and the severity of erythema, pustules, and scaling (desquamation) over 4 body regions (head, trunk, upper limbs and lower limbs).

A higher score indicates a worse disease state, while a score of 0 indicates no disease. GPPASI 75 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 75% reduction.

Proportion of patients with GPPASI 75 at Week 4 is reported.

Randomized Set (RS) (via estimand EN-NRI): EN = Any assessments after death, or any use of escape medication due to disease worsening prior to Week 1 were considered to represent a non-response. NRI

= Non-response imputation for any missing data.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| At Week 4.           |           |

| End point values                  | Placebo                | Spesolimab 900 mg i.v SD |  |  |
|-----------------------------------|------------------------|--------------------------|--|--|
| Subject group type                | Reporting group        | Reporting group          |  |  |
| Number of subjects analysed       | 18 <sup>[7]</sup>      | 35 <sup>[8]</sup>        |  |  |
| Units: Proportion of participants |                        |                          |  |  |
| number (confidence interval 95%)  | 0.111 (0.031 to 0.328) | 0.457 (0.305 to 0.618)   |  |  |

Notes:

[7] - RS via estimand EN-NRI

[8] - RS via estimand EN-NRI

## Statistical analyses

|                            |                        |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 3 |
|----------------------------|------------------------|

Statistical analysis description:

The Suissa-Shuster Z-pooled test was implemented to test the treatment effect on the RS (estimand EN) at a 1-sided, alpha level of 0.025. Confidence intervals (95%) around the risk difference were produced using the Chan and Zhang method.

|                                         |                                    |
|-----------------------------------------|------------------------------------|
| Comparison groups                       | Placebo v Spesolimab 900 mg i.v SD |
| Number of subjects included in analysis | 53                                 |
| Analysis specification                  | Pre-specified                      |
| Analysis type                           |                                    |
| P-value                                 | = 0.0081 <sup>[9]</sup>            |
| Method                                  | Suissa-Shuster Z-pooled test       |
| Parameter estimate                      | Risk difference (RD)               |
| Point estimate                          | 0.346                              |
| Confidence interval                     |                                    |
| level                                   | 95 %                               |
| sides                                   | 2-sided                            |
| lower limit                             | 0.058                              |
| upper limit                             | 0.554                              |

Notes:

[9] - One-sided P Value.

## Secondary: Change from baseline in Pain Visual Analog Scale (VAS) score at Week 4

|                 |                                                                        |
|-----------------|------------------------------------------------------------------------|
| End point title | Change from baseline in Pain Visual Analog Scale (VAS) score at Week 4 |
|-----------------|------------------------------------------------------------------------|

End point description:

The pain Visual Analogue Scale (VAS) is a participant-administered single-item scale designed to measure skin pain intensity from generalized pustular psoriasis (GPP) using a 100 millimeter (mm) horizontal VAS. Overall severity of participant's skin pain from GPP is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (pain as bad as one can imagine). Change from baseline was calculated by subtracting the VAS score at baseline from the VAS score at Week 4.

Median and Interquartile range of the absolute change from baseline at Week 4 in the VAS score are reported. A negative change indicates an improvement from baseline.

-99999 and 99999= Non- response=Worst possible outcome.

|                         |           |
|-------------------------|-----------|
| End point type          | Secondary |
| End point timeframe:    |           |
| Baseline and at Week 4. |           |

| End point values                      | Placebo                 | Spesolimab 900 mg i.v SD |  |  |
|---------------------------------------|-------------------------|--------------------------|--|--|
| Subject group type                    | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed           | 18 <sup>[10]</sup>      | 35 <sup>[11]</sup>       |  |  |
| Units: Units on a scale               |                         |                          |  |  |
| median (inter-quartile range (Q1-Q3)) | 99999 (-99999 to 99999) | -22.45 (-70.41 to 99999) |  |  |

Notes:

[10] - RS-last observation carried forward (LOCF)

[11] - RS-LOCF

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                           | Statistical Analysis 4             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                    |                                    |
| The effect of spesolimab was evaluated by a Wilcoxon rank test using the RS. Any assessments after death, the use of escape medication (before or after Day 8), open label spesolimab on Day 8, or rescue medication with spesolimab after Day 8 were assigned worst ranks for the testing. Missing data at Week 4 were imputed and handled via assessment of ranks. |                                    |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                    | Placebo v Spesolimab 900 mg i.v SD |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                              | 53                                 |
| Analysis specification                                                                                                                                                                                                                                                                                                                                               | Pre-specified                      |
| Analysis type                                                                                                                                                                                                                                                                                                                                                        |                                    |
| P-value                                                                                                                                                                                                                                                                                                                                                              | = 0.0012 <sup>[12]</sup>           |
| Method                                                                                                                                                                                                                                                                                                                                                               | Wilcoxon (Mann-Whitney)            |

Notes:

[12] - One-sided P Value.

## Secondary: Change from baseline in Psoriasis Symptom Scale (PSS) score at Week 4

|                 |                                                                       |
|-----------------|-----------------------------------------------------------------------|
| End point title | Change from baseline in Psoriasis Symptom Scale (PSS) score at Week 4 |
|-----------------|-----------------------------------------------------------------------|

End point description:

The Psoriasis Symptom Scale (PSS) is a 4-item patient-reported outcome (PRO) instrument that assess the severity of psoriasis symptoms in patients with moderate to severe psoriasis. The symptoms included are: pain, redness, itching, and burning. The symptom severity was assessed using a 5 point scale ranging from 0 to 4 where 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. The symptom scores are added to an unweighted total score (range: 0 to 16). A lower PSS score indicates a better outcome.

Randomized Set (RS) (via estimand EN-LOCF): EN = Death or any use of escape medication before or after Day 8, open-label spesolimab at Day 8, or rescue medication with spesolimab after Day 8 were considered to represent a non-response and assigned with the worst possible outcomes in rank analysis. LOCF = last observation carried forward imputation for any missing data. -99999 and 99999= Non- response=Worst possible outcome.

|                         |           |
|-------------------------|-----------|
| End point type          | Secondary |
| End point timeframe:    |           |
| Baseline and at Week 4. |           |

| End point values                      | Placebo                 | Spesolimab 900 mg i.v SD |  |  |
|---------------------------------------|-------------------------|--------------------------|--|--|
| Subject group type                    | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed           | 18 <sup>[13]</sup>      | 35 <sup>[14]</sup>       |  |  |
| Units: Units on a scale               |                         |                          |  |  |
| median (inter-quartile range (Q1-Q3)) | 99999 (-99999 to 99999) | -2.0 (-9.0 to 99999)     |  |  |

Notes:

[13] - RS via estimand EN-LOCF

[14] - RS via estimand EN-LOCF

## Statistical analyses

| Statistical analysis title | Statistical Analysis 5 |
|----------------------------|------------------------|
|----------------------------|------------------------|

Statistical analysis description:

The effect of spesolimab was evaluated by a Wilcoxon rank test using the RS. Any assessments after death, the use of escape medication (before or after Day 8), open label spesolimab on Day 8, or rescue medication with spesolimab after Day 8 were assigned worst ranks for the testing. Missing data at Week 4 were imputed and handled via assessment of ranks.

|                                         |                                    |
|-----------------------------------------|------------------------------------|
| Comparison groups                       | Placebo v Spesolimab 900 mg i.v SD |
| Number of subjects included in analysis | 53                                 |
| Analysis specification                  | Pre-specified                      |
| Analysis type                           |                                    |
| P-value                                 | = 0.0044 <sup>[15]</sup>           |
| Method                                  | Wilcoxon (Mann-Whitney)            |

Notes:

[15] - One-sided P Value.

## Secondary: Change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue score at Week 4

|                 |                                                                                                            |
|-----------------|------------------------------------------------------------------------------------------------------------|
| End point title | Change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue score at Week 4 |
|-----------------|------------------------------------------------------------------------------------------------------------|

End point description:

The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients scored each item on a 5-point scale from 0 to 4 (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). To calculate total FACIT-Fatigue score, which ranges from 0 (extreme fatigue) to 52 (no fatigue), the scores of all questions except for "I have energy" and "I am able to do my usual activities" were reversed by subtracting the observed score from 4 (i.e. 4-observed score). Then, scores of all non-missing questions were summed, multiplied by 13 and divided by the number of answered questions.

Change from baseline was calculated by subtracting the FACIT - Fatigue score at baseline from the FACIT-Fatigue score at Week 4. A positive change indicates an improvement from baseline.

Randomized Set (RS) (via estimand EN-LOCF).

-99999 and 99999 = Non-response = Worst possible outcome.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and at Week 4.

| End point values                      | Placebo                 | Spesolimab 900 mg i.v SD |  |  |
|---------------------------------------|-------------------------|--------------------------|--|--|
| Subject group type                    | Reporting group         | Reporting group          |  |  |
| Number of subjects analysed           | 18 <sup>[16]</sup>      | 35 <sup>[17]</sup>       |  |  |
| Units: Units on a scale               |                         |                          |  |  |
| median (inter-quartile range (Q1-Q3)) | 99999 (-99999 to 99999) | 3.00 (-99999 to 30.00)   |  |  |

Notes:

[16] - RS via estimand EN-LOCF

[17] - RS via estimand EN-LOCF

## Statistical analyses

| Statistical analysis title | Statistical Analysis 6 |
|----------------------------|------------------------|
|----------------------------|------------------------|

Statistical analysis description:

The effect of spesolimab was evaluated by a Wilcoxon rank test using the RS. Any assessments after death, the use of escape medication (before or after Day 8), open label spesolimab on Day 8, or rescue medication with spesolimab after Day 8 were assigned worst ranks for the testing. Missing data at Week 4 were imputed and handled via assessment of ranks.

|                                         |                                    |
|-----------------------------------------|------------------------------------|
| Comparison groups                       | Placebo v Spesolimab 900 mg i.v SD |
| Number of subjects included in analysis | 53                                 |
| Analysis specification                  | Pre-specified                      |
| Analysis type                           |                                    |
| P-value                                 | = 0.0012 <sup>[18]</sup>           |
| Method                                  | Wilcoxon (Mann-Whitney)            |

Notes:

[18] - One-sided P Value.

## Secondary: Proportion of patients with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1 at Week 4

|                 |                                                                                                                            |
|-----------------|----------------------------------------------------------------------------------------------------------------------------|
| End point title | Proportion of patients with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1 at Week 4 |
|-----------------|----------------------------------------------------------------------------------------------------------------------------|

End point description:

GPPGA relied on clinical assessment of the Generalized Pustular Psoriasis (GPP) patient's skin presentation. The GPPGA total score is calculated by taking the mean of the erythema subscore, pustules subscore and scaling/crusting subscore. The severity of each subscore was assessed using a 5 point scale score ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). The final GPPGA score is assigned as follows:

- 0, if scores for all three scores are 0,
- 1, if  $0 < \text{mean} < 1.5$ ,
- 2, if  $1.5 \leq \text{mean} < 2.5$ ,
- 3, if  $2.5 \leq \text{mean} < 3.5$ ,
- 4, if  $\text{mean} \geq 3.5$ .

A lower GPPGA score indicates a better outcome, with 0 being clear and 1 being almost clear. Randomized Set (RS) (via estimand EN-NRI):EN = Any assessments after death, or the use of escape medication (before or after Day 8), or open-label Spesolimab at Day 8, or rescue medication with Spesolimab after Day 8, was considered a non-response. NRI = Non-response imputation for any missing data.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Week 4.

| End point values                  | Placebo                   | Spesolimab<br>900 mg i.v SD |  |  |
|-----------------------------------|---------------------------|-----------------------------|--|--|
| Subject group type                | Reporting group           | Reporting group             |  |  |
| Number of subjects analysed       | 18 <sup>[19]</sup>        | 35 <sup>[20]</sup>          |  |  |
| Units: Proportion of participants |                           |                             |  |  |
| number (confidence interval 95%)  | 0.111 (0.031<br>to 0.328) | 0.486 (0.330<br>to 0.644)   |  |  |

Notes:

[19] - RS via estimand EN-NRI

[20] - RS via estimand EN-NRI

## Statistical analyses

| Statistical analysis title                                                                           | Statistical Analysis 7             |
|------------------------------------------------------------------------------------------------------|------------------------------------|
| Statistical analysis description:                                                                    |                                    |
| Confidence intervals (95%) around the risk difference were produced using the Chan and Zhang method. |                                    |
| Comparison groups                                                                                    | Placebo v Spesolimab 900 mg i.v SD |
| Number of subjects included in analysis                                                              | 53                                 |
| Analysis specification                                                                               | Pre-specified                      |
| Analysis type                                                                                        |                                    |
| Parameter estimate                                                                                   | Risk difference (RD)               |
| Point estimate                                                                                       | 0.375                              |
| Confidence interval                                                                                  |                                    |
| level                                                                                                | 95 %                               |
| sides                                                                                                | 2-sided                            |
| lower limit                                                                                          | 0.058                              |
| upper limit                                                                                          | 0.581                              |

## Secondary: Proportion of patients with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation sub-score of 0 indicating no visible pustules at Week 4

|                 |                                                                                                                                                                      |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Proportion of patients with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation sub-score of 0 indicating no visible pustules at Week 4 |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) relies on clinical assessment of the Generalized Pustular Psoriasis (GPP) patient's skin presentation. The investigator (or qualified site personnel) scores the erythema, pustules, and scaling of all GPP lesions from 0 to 4.

The GPPGA pustulation subscore ranges from 0 to 4 where:

0 = clear;

1 = almost clear;

2 = mild;

3 = moderate;

4 = severe.

A lower GPPGA pustulation subscore indicates a better outcome.

Randomized Set (RS) (via estimand EN-NRI): EN = Any assessments after death, or the use of escape medication (before or after Day 8), or open-label spesolimab at Day 8, or rescue medication with spesolimab after Day 8, was considered a non-response. NRI = Non-response imputation for any missing data.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Week 4.

| End point values                  | Placebo                | Spesolimab 900 mg i.v SD |  |  |
|-----------------------------------|------------------------|--------------------------|--|--|
| Subject group type                | Reporting group        | Reporting group          |  |  |
| Number of subjects analysed       | 18 <sup>[21]</sup>     | 35 <sup>[22]</sup>       |  |  |
| Units: Proportion of participants |                        |                          |  |  |
| number (confidence interval 95%)  | 0.111 (0.031 to 0.328) | 0.514 (0.356 to 0.670)   |  |  |

Notes:

[21] - RS via estimand EN-NRI

[22] - RS via estimand EN-NRI

## Statistical analyses

| Statistical analysis title                                                                           | Statistical Analysis 8             |
|------------------------------------------------------------------------------------------------------|------------------------------------|
| Statistical analysis description:                                                                    |                                    |
| Confidence intervals (95%) around the risk difference were produced using the Chan and Zhang method. |                                    |
| Comparison groups                                                                                    | Placebo v Spesolimab 900 mg i.v SD |
| Number of subjects included in analysis                                                              | 53                                 |
| Analysis specification                                                                               | Pre-specified                      |
| Analysis type                                                                                        |                                    |
| Parameter estimate                                                                                   | Risk difference (RD)               |
| Point estimate                                                                                       | 0.403                              |
| Confidence interval                                                                                  |                                    |
| level                                                                                                | 95 %                               |
| sides                                                                                                | 2-sided                            |
| lower limit                                                                                          | 0.096                              |
| upper limit                                                                                          | 0.607                              |

## Secondary: Proportion of patients with a Generalized Pustular Psoriasis Area and Severity Index (GPPASI) 50 at Week 4

|                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                           | Proportion of patients with a Generalized Pustular Psoriasis Area and Severity Index (GPPASI) 50 at Week 4 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                            |
| Generalized Pustular Psoriasis Area and Severity Index (GPPASI) provides a numeric scoring for a patient's overall Generalized Pustular Psoriasis (GPP) disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin affected by erythema, pustules, and scaling and the severity of erythema, pustules, and scaling (desquamation) over 4 body regions (head, trunk, upper limbs and lower limbs). |                                                                                                            |
| A higher score indicates a worse disease state, while a score of 0 indicates no disease. GPPASI 50 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 50 % reduction.                                                                                                                                                                                              |                                                                                                            |
| Randomized Set (RS) (via estimand EN-NRI):EN = Any assessments after death, or the use of escape medication (before or after Day 8), or open-label spesolimab at Day 8, or rescue medication with spesolimab after Day 8, was considered a non-response. NRI = Non-response imputation for any missing data.                                                                                                                              |                                                                                                            |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                            | Secondary                                                                                                  |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                            |
| At Week 4.                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                            |



| End point values                  | Placebo                | Spesolimab 900 mg i.v SD |  |  |
|-----------------------------------|------------------------|--------------------------|--|--|
| Subject group type                | Reporting group        | Reporting group          |  |  |
| Number of subjects analysed       | 18 <sup>[23]</sup>     | 35 <sup>[24]</sup>       |  |  |
| Units: Proportion of participants |                        |                          |  |  |
| number (confidence interval 95%)  | 0.111 (0.031 to 0.328) | 0.543 (0.382 to 0.695)   |  |  |

Notes:

[23] - RS via estimand EN-NRI

[24] - RS via estimand EN-NRI

## Statistical analyses

| Statistical analysis title                                                                           | Statistical Analysis 9             |
|------------------------------------------------------------------------------------------------------|------------------------------------|
| Statistical analysis description:                                                                    |                                    |
| Confidence intervals (95%) around the risk difference were produced using the Chan and Zhang method. |                                    |
| Comparison groups                                                                                    | Placebo v Spesolimab 900 mg i.v SD |
| Number of subjects included in analysis                                                              | 53                                 |
| Analysis specification                                                                               | Pre-specified                      |
| Analysis type                                                                                        |                                    |
| Parameter estimate                                                                                   | Risk difference (RD)               |
| Point estimate                                                                                       | 0.432                              |
| Confidence interval                                                                                  |                                    |
| level                                                                                                | 95 %                               |
| sides                                                                                                | 2-sided                            |
| lower limit                                                                                          | 0.096                              |
| upper limit                                                                                          | 0.636                              |

## Secondary: Percent change in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) from baseline at Week 4

|                 |                                                                                                           |
|-----------------|-----------------------------------------------------------------------------------------------------------|
| End point title | Percent change in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) from baseline at Week 4 |
|-----------------|-----------------------------------------------------------------------------------------------------------|

End point description:

Generalized Pustular Psoriasis Area and Severity Index (GPPASI) provides a numeric scoring for a patient's overall Generalized Pustular Psoriasis (GPP) disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin affected by erythema, pustules, and scaling and the severity of erythema, pustules, and scaling (desquamation) over 4 body regions (head, trunk, upper limbs and lower limbs).

A higher score indicates a worse disease state, while a score of 0 indicates no disease.

The percent change from baseline at Week 4 is calculated as:

% GPPASI change from baseline = (GPPASI at Week 4 - GPPASI at baseline) \*100/(GPPASI at baseline).

If % GPPASI change from baseline is positive, it means the disease is becoming worse. RS via estimand EN-LOCF.

-99999 and 99999= Non- response=Worst possible outcome.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and at Week 4.

| End point values                      | Placebo                    | Spesolimab<br>900 mg i.v SD |  |  |
|---------------------------------------|----------------------------|-----------------------------|--|--|
| Subject group type                    | Reporting group            | Reporting group             |  |  |
| Number of subjects analysed           | 18 <sup>[25]</sup>         | 35 <sup>[26]</sup>          |  |  |
| Units: Percentage change              |                            |                             |  |  |
| median (inter-quartile range (Q1-Q3)) | 99999 (-99999<br>to 99999) | -60.50 (-88.37<br>to 99999) |  |  |

Notes:

[25] - RS via estimand EN-LOCF

[26] - RS via estimand EN-LOCF

## Statistical analyses

No statistical analyses for this end point

## Secondary: Proportion of patients with a Generalized Pustular Psoriasis Area and Severity Index (GPPASI) 50 at Week 1

|                 |                                                                                                            |
|-----------------|------------------------------------------------------------------------------------------------------------|
| End point title | Proportion of patients with a Generalized Pustular Psoriasis Area and Severity Index (GPPASI) 50 at Week 1 |
|-----------------|------------------------------------------------------------------------------------------------------------|

End point description:

Generalized Pustular Psoriasis Area and Severity Index (GPPASI) provides a numeric scoring for a patient's overall Generalized Pustular Psoriasis (GPP) disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin affected by erythema, pustules, and scaling and the severity of erythema, pustules, and scaling (desquamation) over 4 body regions (head, trunk, upper limbs and lower limbs).

A higher score indicates a worse disease state, while a score of 0 indicates no disease. GPPASI 50 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 50 % reduction.

Randomized Set (RS) (via estimand EN-NRI).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Week 1.

| End point values                  | Placebo                   | Spesolimab<br>900 mg i.v SD |  |  |
|-----------------------------------|---------------------------|-----------------------------|--|--|
| Subject group type                | Reporting group           | Reporting group             |  |  |
| Number of subjects analysed       | 18 <sup>[27]</sup>        | 35 <sup>[28]</sup>          |  |  |
| Units: Proportion of participants |                           |                             |  |  |
| number (confidence interval 95%)  | 0.278 (0.125<br>to 0.509) | 0.429 (0.280<br>to 0.591)   |  |  |

Notes:

[27] - RS via estimand EN-NRI

[28] - RS via estimand EN-NRI

## Statistical analyses

|                            |                         |
|----------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 10 |
|----------------------------|-------------------------|

Statistical analysis description:

Confidence intervals (95%) around the risk difference were produced using the Chan and Zhang method.

|                                         |                                    |
|-----------------------------------------|------------------------------------|
| Comparison groups                       | Placebo v Spesolimab 900 mg i.v SD |
| Number of subjects included in analysis | 53                                 |
| Analysis specification                  | Pre-specified                      |
| Analysis type                           |                                    |
| Parameter estimate                      | Risk difference (RD)               |
| Point estimate                          | 0.151                              |
| Confidence interval                     |                                    |
| level                                   | 95 %                               |
| sides                                   | 2-sided                            |
| lower limit                             | -0.138                             |
| upper limit                             | 0.401                              |

## Secondary: Percent change in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) from baseline at Week 1

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Percent change in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) from baseline at Week 1 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                           |
| <p>Generalized Pustular Psoriasis Area and Severity Index (GPPASI) provides a numeric scoring for a patient's overall Generalized Pustular Psoriasis (GPP) disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin affected by erythema, pustules, and scaling and the severity of erythema, pustules, and scaling (desquamation) over 4 body regions (head, trunk, upper limbs and lower limbs).</p> <p>A higher score indicates a worse disease state, while a score of 0 indicates no disease.</p> <p>The percent change from baseline at Week 1 is calculated as:</p> <p>% GPPASI change from baseline = (GPPASI at Week 1 - GPPASI at baseline) *100/GPPASI at baseline.</p> <p>If % GPPASI change from baseline is positive, it means the disease is becoming worse.</p> <p>Randomized Set (RS) via estimand EN-LOCF.</p> |                                                                                                           |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Secondary                                                                                                 |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                           |
| At Week 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                           |

| End point values                      | Placebo                | Spesolimab 900 mg i.v SD |  |  |
|---------------------------------------|------------------------|--------------------------|--|--|
| Subject group type                    | Reporting group        | Reporting group          |  |  |
| Number of subjects analysed           | 18 <sup>[29]</sup>     | 35 <sup>[30]</sup>       |  |  |
| Units: Percentage change              |                        |                          |  |  |
| median (inter-quartile range (Q1-Q3)) | 1.02 (-60.47 to 36.68) | -42.80 (-69.84 to 9.49)  |  |  |

Notes:

[29] - RS via estimand EN-LOCF

[30] - RS via estimand EN-LOCF

## Statistical analyses

|                                                                                                                                                                                                                                                                                                                     |                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| Statistical analysis title                                                                                                                                                                                                                                                                                          | Statistical Analysis 11            |
| Statistical analysis description:                                                                                                                                                                                                                                                                                   |                                    |
| <p>Any assessments after death, the use of escape medication (before or after Day 8), open label spesolimab on Day 8, or rescue medication with spesolimab after Day 8 and assigned with the worst possible outcomes in rank analysis. Missing data at Week 4 were imputed and handled via assessment of ranks.</p> |                                    |
| Comparison groups                                                                                                                                                                                                                                                                                                   | Placebo v Spesolimab 900 mg i.v SD |

|                                         |                                  |
|-----------------------------------------|----------------------------------|
| Number of subjects included in analysis | 53                               |
| Analysis specification                  | Pre-specified                    |
| Analysis type                           |                                  |
| Parameter estimate                      | Median difference (final values) |
| Point estimate                          | -16.88                           |
| Confidence interval                     |                                  |
| level                                   | 95 %                             |
| sides                                   | 2-sided                          |
| lower limit                             | -67.32                           |
| upper limit                             | 12.76                            |

## Secondary: Occurrence of Treatment Emergent Adverse Events (TEAEs) up to Week 1

|                 |                                                                      |
|-----------------|----------------------------------------------------------------------|
| End point title | Occurrence of Treatment Emergent Adverse Events (TEAEs) up to Week 1 |
|-----------------|----------------------------------------------------------------------|

End point description:

TEAEs were all Adverse Events (AEs) occurring between start of treatment and Day 8 (Day 8 excluded). AEs that started before first drug intake and deteriorated under treatment were also considered as 'treatment-emergent'.

The exposure-adjusted incidence rate was calculated as:

Incidence rate [1/100 patients-years] =  $100 \times \text{number of patients with AE} / \text{Total AE specific time at risk [patient-years]}$

where: Time at risk [patient-years] = (date of onset of TEAE – study drug start date + 1) / 365.25

Safety Analysis set (SAF): This patient set included all patients who were randomized and received at least one dose of study drug on Day 1. Patients were analyzed according to the actual treatment received.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From start of treatment until Day 7, up to 7 days.

| End point values                            | Placebo            | Spesolimab 900 mg i.v SD |  |  |
|---------------------------------------------|--------------------|--------------------------|--|--|
| Subject group type                          | Reporting group    | Reporting group          |  |  |
| Number of subjects analysed                 | 18 <sup>[31]</sup> | 35 <sup>[32]</sup>       |  |  |
| Units: events per 100 patient-years at risk |                    |                          |  |  |
| number (not applicable)                     | 6445.6             | 8650.7                   |  |  |

Notes:

[31] - SAF

[32] - SAF

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of patients with Treatment Emergent Adverse Events (TEAEs) up to Week 1

|                 |                                                                                |
|-----------------|--------------------------------------------------------------------------------|
| End point title | Number of patients with Treatment Emergent Adverse Events (TEAEs) up to Week 1 |
|-----------------|--------------------------------------------------------------------------------|

End point description:

TEAEs were all Adverse Events (AEs) occurring between start of treatment and Day 8 (Day 8 excluded). AEs that started before first drug intake and deteriorated under treatment were also considered as 'treatment-emergent'.

Safety Analysis set (SAF): This patient set included all patients who were randomized and received at least one dose of study drug on Day 1. Patients were analyzed according to the actual treatment received.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From start of treatment until Day 7, up to 7 days.

| End point values            | Placebo            | Spesolimab<br>900 mg i.v SD |  |  |
|-----------------------------|--------------------|-----------------------------|--|--|
| Subject group type          | Reporting group    | Reporting group             |  |  |
| Number of subjects analysed | 18 <sup>[33]</sup> | 35 <sup>[34]</sup>          |  |  |
| Units: Participants         | 12                 | 27                          |  |  |

Notes:

[33] - SAF

[34] - SAF

## Statistical analyses

No statistical analyses for this end point

## Secondary: Occurrence of Treatment Emergent Adverse Events (TEAEs) within the treatment phase

|                 |                                                                                    |
|-----------------|------------------------------------------------------------------------------------|
| End point title | Occurrence of Treatment Emergent Adverse Events (TEAEs) within the treatment phase |
|-----------------|------------------------------------------------------------------------------------|

End point description:

TEAEs were all Adverse Events (AEs) occurring between start of treatment and end of the residual effect period (REP) (16 weeks). AEs that started before first drug intake and deteriorated under treatment were also considered as 'treatment-emergent'.

The exposure-adjusted incidence rate was calculated as:

Incidence rate [1/100 patients-years] =  $100 \times \text{number of patients with AE} / \text{Total AE specific time at risk [patient-years]}$

where Time at risk

where: Time at risk [patient-years] = (date of onset of TEAE – study drug start date + 1) / 365.25

If, for a patient, the selected TEAE did not occur then the time at risk was censored at min

- Date of death

- For patients who did not roll over into the Open Label Extension (OLE) study: last contact date Visit14/15

- For patients who rolled over into the OLE study: the 1st dose in the OLE study

- Drug stop date + 112 days

- Date of Day 8 if OL spesolimab was given

- Date of rescue medication if spesolimab was given.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From start of treatment until end of the residual effect period (REP) but censored at any use of open label spesolimab, up to 16 weeks.

| End point values                            | Placebo            | Spesolimab<br>900 mg i.v SD |  |  |
|---------------------------------------------|--------------------|-----------------------------|--|--|
| Subject group type                          | Reporting group    | Reporting group             |  |  |
| Number of subjects analysed                 | 18 <sup>[35]</sup> | 35 <sup>[36]</sup>          |  |  |
| Units: events per 100 patient-years at risk |                    |                             |  |  |
| number (not applicable)                     | 3083.3             | 2391.0                      |  |  |

Notes:

[35] - SAF.

[36] - SAF

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of patients with Treatment Emergent Adverse Events (TEAEs) within the treatment phase

|                 |                                                                                              |
|-----------------|----------------------------------------------------------------------------------------------|
| End point title | Number of patients with Treatment Emergent Adverse Events (TEAEs) within the treatment phase |
|-----------------|----------------------------------------------------------------------------------------------|

End point description:

TEAEs were all Adverse Events (AEs) occurring between start of treatment and end of the residual effect period (REP) (16 weeks). AEs that started before first drug intake and deteriorated under treatment were also considered as 'treatment-emergent'.

Safety Analysis set (SAF): This patient set included all patients who were randomized and received at least one dose of study drug on Day 1. Patients were analyzed according to the actual treatment received.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From start of treatment until end of the residual effect period (REP) but censored at any use of open label spesolimab, up to 16 weeks.

| End point values            | Placebo            | Spesolimab<br>900 mg i.v SD |  |  |
|-----------------------------|--------------------|-----------------------------|--|--|
| Subject group type          | Reporting group    | Reporting group             |  |  |
| Number of subjects analysed | 18 <sup>[37]</sup> | 35 <sup>[38]</sup>          |  |  |
| Units: Participants         | 13                 | 29                          |  |  |

Notes:

[37] - SAF

[38] - SAF

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Placebo and Spesolimab 900 mg i.v. SD arms: From the start of infusion of randomized medication at Day 1 (D1) of Week 1 (Wk1) until the end of its REP (16 weeks) but were censored at any use of open-label (OL) spesolimab.

Adverse event reporting additional description:

Safety Analysis set (SAF)

OL Spesolimab: From the start of OL spesolimab at Wk1/D8 until the end of its REP (16 weeks) but were censored at any use of rescue medication with spesolimab.

Rescue Spesolimab: From the start of rescue medication with spesolimab until the end of its REP (16 weeks).

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                    |        |
|--------------------|--------|
| Dictionary name    | MedDRA |
| Dictionary version | 23.1   |

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Patients received intravenously (i.v.) solution for infusion containing 0 mg of placebo to spesolimab on Day 1 (D1) of Week 1 (Wk1). Based on the subsequent treatment response, participants were then to be followed up for 12 to 28 weeks. If the severity and progression of the disease worsened within the first week the investigator could treat the patient with a Standard of Care (SoC) treatment of his/her choice (escape medication). If the disease condition was stable, it was recommended to wait until the primary endpoint visit (Wk1/D8) before prescribing SoC since there was an option to administer open label (OL) spesolimab instead at this time. If SoC was administered within the first week, the patient was not eligible to receive treatment with a single OL i.v. dose of 900 mg spesolimab on D8. If the condition of the patients worsened after Wk1/D8 patients were eligible to receive rescue treatment with open label spesolimab after Wk1 to Wk 12.

|                       |                               |
|-----------------------|-------------------------------|
| Reporting group title | Rescue Spesolimab 900 mg i.v. |
|-----------------------|-------------------------------|

Reporting group description:

This arm included patients who in addition to the randomized treatment (either intravenously (i.v.) placebo solution to spesolimab at Day 1 or 900 milligram (mg) i.v. spesolimab at Day 1) also one single rescue i.v. dose of 900 mg spesolimab between Week 1(Wk 1) to Week 12 (Wk 12).

|                       |                                           |
|-----------------------|-------------------------------------------|
| Reporting group title | Open Label (OL) D8 Spesolimab 900 mg i.v. |
|-----------------------|-------------------------------------------|

Reporting group description:

This arm included patients who in addition to the randomized treatment (either intravenously (i.v.) placebo solution to spesolimab at Day 1 or 900 milligram (mg) i.v. spesolimab at Day 1) received also Open Label Treatment with 900 mg I.V spesolimab at Week 1 (Wk1)/Day 8 (D8).

|                       |                           |
|-----------------------|---------------------------|
| Reporting group title | Spesolimab 900 mg i.v. SD |
|-----------------------|---------------------------|

Reporting group description:

Patients received intravenously (i.v.) a single dose of solution for infusion containing 900 mg of spesolimab on Day 1 (D1) of Week 1 (Wk1). Based on the subsequent treatment response, participants were then to be followed up for 12 to 28 Wk.

If the severity and progression of the disease worsened within the first week the investigator could treat the patient with a Standard of Care (SoC) treatment of his/her choice. If the disease condition was stable, it was recommended to wait until the primary endpoint visit (Wk1/D8) before prescribing SoC since there was an option to administer open label (OL) spesolimab instead at this time. If SoC was administered within the first week, the patient was not eligible to receive treatment with a single OL i.v. dose of 900 mg spesolimab on D8.

If the condition of the patient worsened after Wk1/D8 patients were eligible to receive rescue treatment with open label spesolimab (only one single rescue i.v. dose of 900 mg spesolimab) after Wk1 to Wk 12.

| Serious adverse events                                                 | Placebo         | Rescue Spesolimab<br>900 mg i.v. | Open Label (OL) D8<br>Spesolimab 900 mg<br>i.v. |
|------------------------------------------------------------------------|-----------------|----------------------------------|-------------------------------------------------|
| Total subjects affected by serious<br>adverse events                   |                 |                                  |                                                 |
| subjects affected / exposed                                            | 3 / 18 (16.67%) | 2 / 6 (33.33%)                   | 6 / 27 (22.22%)                                 |
| number of deaths (all causes)                                          | 0               | 0                                | 0                                               |
| number of deaths resulting from<br>adverse events                      | 0               | 0                                | 0                                               |
| Neoplasms benign, malignant and<br>unspecified (incl cysts and polyps) |                 |                                  |                                                 |
| Squamous cell carcinoma of skin                                        |                 |                                  |                                                 |
| subjects affected / exposed                                            | 0 / 18 (0.00%)  | 0 / 6 (0.00%)                    | 1 / 27 (3.70%)                                  |
| occurrences causally related to<br>treatment / all                     | 0 / 0           | 0 / 0                            | 0 / 1                                           |
| deaths causally related to<br>treatment / all                          | 0 / 0           | 0 / 0                            | 0 / 0                                           |
| Hepatobiliary disorders                                                |                 |                                  |                                                 |
| Drug-induced liver injury                                              |                 |                                  |                                                 |
| subjects affected / exposed                                            | 0 / 18 (0.00%)  | 0 / 6 (0.00%)                    | 0 / 27 (0.00%)                                  |
| occurrences causally related to<br>treatment / all                     | 0 / 0           | 0 / 0                            | 0 / 0                                           |
| deaths causally related to<br>treatment / all                          | 0 / 0           | 0 / 0                            | 0 / 0                                           |
| Skin and subcutaneous tissue disorders                                 |                 |                                  |                                                 |
| Drug reaction with eosinophilia and<br>systemic symptoms               |                 |                                  |                                                 |
| subjects affected / exposed                                            | 0 / 18 (0.00%)  | 0 / 6 (0.00%)                    | 0 / 27 (0.00%)                                  |
| occurrences causally related to<br>treatment / all                     | 0 / 0           | 0 / 0                            | 0 / 0                                           |
| deaths causally related to<br>treatment / all                          | 0 / 0           | 0 / 0                            | 0 / 0                                           |
| Psoriasis                                                              |                 |                                  |                                                 |
| subjects affected / exposed                                            | 0 / 18 (0.00%)  | 0 / 6 (0.00%)                    | 1 / 27 (3.70%)                                  |
| occurrences causally related to<br>treatment / all                     | 0 / 0           | 0 / 0                            | 0 / 1                                           |
| deaths causally related to<br>treatment / all                          | 0 / 0           | 0 / 0                            | 0 / 0                                           |
| Pustular psoriasis                                                     |                 |                                  |                                                 |
| subjects affected / exposed                                            | 3 / 18 (16.67%) | 2 / 6 (33.33%)                   | 3 / 27 (11.11%)                                 |
| occurrences causally related to<br>treatment / all                     | 2 / 3           | 1 / 2                            | 2 / 3                                           |
| deaths causally related to<br>treatment / all                          | 0 / 0           | 0 / 0                            | 0 / 0                                           |
| Musculoskeletal and connective tissue<br>disorders                     |                 |                                  |                                                 |
| Arthritis                                                              |                 |                                  |                                                 |
| subjects affected / exposed                                            | 0 / 18 (0.00%)  | 0 / 6 (0.00%)                    | 0 / 27 (0.00%)                                  |
| occurrences causally related to<br>treatment / all                     | 0 / 0           | 0 / 0                            | 0 / 0                                           |
| deaths causally related to<br>treatment / all                          | 0 / 0           | 0 / 0                            | 0 / 0                                           |
| Infections and infestations                                            |                 |                                  |                                                 |



|                                                 |                |               |                |
|-------------------------------------------------|----------------|---------------|----------------|
| Influenza                                       |                |               |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 6 (0.00%) | 1 / 27 (3.70%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 1 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Urinary tract infection                         |                |               |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |

|                                                                     |                              |  |  |
|---------------------------------------------------------------------|------------------------------|--|--|
| <b>Serious adverse events</b>                                       | Spesolimab 900 mg<br>i.v. SD |  |  |
| Total subjects affected by serious adverse events                   |                              |  |  |
| subjects affected / exposed                                         | 6 / 35 (17.14%)              |  |  |
| number of deaths (all causes)                                       | 0                            |  |  |
| number of deaths resulting from adverse events                      | 0                            |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                              |  |  |
| Squamous cell carcinoma of skin                                     |                              |  |  |
| subjects affected / exposed                                         | 0 / 35 (0.00%)               |  |  |
| occurrences causally related to treatment / all                     | 0 / 0                        |  |  |
| deaths causally related to treatment / all                          | 0 / 0                        |  |  |
| Hepatobiliary disorders                                             |                              |  |  |
| Drug-induced liver injury                                           |                              |  |  |
| subjects affected / exposed                                         | 1 / 35 (2.86%)               |  |  |
| occurrences causally related to treatment / all                     | 1 / 1                        |  |  |
| deaths causally related to treatment / all                          | 0 / 0                        |  |  |
| Skin and subcutaneous tissue disorders                              |                              |  |  |
| Drug reaction with eosinophilia and systemic symptoms               |                              |  |  |
| subjects affected / exposed                                         | 2 / 35 (5.71%)               |  |  |
| occurrences causally related to treatment / all                     | 2 / 2                        |  |  |
| deaths causally related to treatment / all                          | 0 / 0                        |  |  |
| Psoriasis                                                           |                              |  |  |
| subjects affected / exposed                                         | 0 / 35 (0.00%)               |  |  |
| occurrences causally related to treatment / all                     | 0 / 0                        |  |  |
| deaths causally related to treatment / all                          | 0 / 0                        |  |  |
| Pustular psoriasis                                                  |                              |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 4 / 35 (11.43%) |  |  |
| occurrences causally related to treatment / all | 0 / 4           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Musculoskeletal and connective tissue disorders |                 |  |  |
| Arthritis                                       |                 |  |  |
| subjects affected / exposed                     | 1 / 35 (2.86%)  |  |  |
| occurrences causally related to treatment / all | 1 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Infections and infestations                     |                 |  |  |
| Influenza                                       |                 |  |  |
| subjects affected / exposed                     | 0 / 35 (0.00%)  |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Urinary tract infection                         |                 |  |  |
| subjects affected / exposed                     | 1 / 35 (2.86%)  |  |  |
| occurrences causally related to treatment / all | 1 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | Placebo          | Rescue Spesolimab<br>900 mg i.v. | Open Label (OL) D8<br>Spesolimab 900 mg<br>i.v. |
|-------------------------------------------------------|------------------|----------------------------------|-------------------------------------------------|
| Total subjects affected by non-serious adverse events |                  |                                  |                                                 |
| subjects affected / exposed                           | 13 / 18 (72.22%) | 4 / 6 (66.67%)                   | 14 / 27 (51.85%)                                |
| Vascular disorders                                    |                  |                                  |                                                 |
| Haemorrhage                                           |                  |                                  |                                                 |
| subjects affected / exposed                           | 0 / 18 (0.00%)   | 1 / 6 (16.67%)                   | 0 / 27 (0.00%)                                  |
| occurrences (all)                                     | 0                | 1                                | 0                                               |
| Hypotension                                           |                  |                                  |                                                 |
| subjects affected / exposed                           | 1 / 18 (5.56%)   | 0 / 6 (0.00%)                    | 0 / 27 (0.00%)                                  |
| occurrences (all)                                     | 1                | 0                                | 0                                               |
| General disorders and administration site conditions  |                  |                                  |                                                 |
| Asthenia                                              |                  |                                  |                                                 |
| subjects affected / exposed                           | 1 / 18 (5.56%)   | 0 / 6 (0.00%)                    | 1 / 27 (3.70%)                                  |
| occurrences (all)                                     | 1                | 0                                | 1                                               |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| Fatigue                                         |                 |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%)  | 0 / 6 (0.00%)  | 0 / 27 (0.00%) |
| occurrences (all)                               | 0               | 0              | 0              |
| Inflammation                                    |                 |                |                |
| subjects affected / exposed                     | 1 / 18 (5.56%)  | 0 / 6 (0.00%)  | 0 / 27 (0.00%) |
| occurrences (all)                               | 2               | 0              | 0              |
| Oedema peripheral                               |                 |                |                |
| subjects affected / exposed                     | 1 / 18 (5.56%)  | 0 / 6 (0.00%)  | 0 / 27 (0.00%) |
| occurrences (all)                               | 1               | 0              | 0              |
| Pyrexia                                         |                 |                |                |
| subjects affected / exposed                     | 4 / 18 (22.22%) | 2 / 6 (33.33%) | 2 / 27 (7.41%) |
| occurrences (all)                               | 4               | 3              | 2              |
| Reproductive system and breast disorders        |                 |                |                |
| Dysmenorrhoea                                   |                 |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%)  | 1 / 6 (16.67%) | 0 / 27 (0.00%) |
| occurrences (all)                               | 0               | 1              | 0              |
| Hypomenorrhoea                                  |                 |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%)  | 1 / 6 (16.67%) | 0 / 27 (0.00%) |
| occurrences (all)                               | 0               | 1              | 0              |
| Respiratory, thoracic and mediastinal disorders |                 |                |                |
| Cough                                           |                 |                |                |
| subjects affected / exposed                     | 1 / 18 (5.56%)  | 0 / 6 (0.00%)  | 1 / 27 (3.70%) |
| occurrences (all)                               | 1               | 0              | 1              |
| Psychiatric disorders                           |                 |                |                |
| Anxiety                                         |                 |                |                |
| subjects affected / exposed                     | 1 / 18 (5.56%)  | 0 / 6 (0.00%)  | 0 / 27 (0.00%) |
| occurrences (all)                               | 1               | 0              | 0              |
| Insomnia                                        |                 |                |                |
| subjects affected / exposed                     | 1 / 18 (5.56%)  | 0 / 6 (0.00%)  | 0 / 27 (0.00%) |
| occurrences (all)                               | 2               | 0              | 0              |
| Investigations                                  |                 |                |                |
| Blood lactate dehydrogenase increased           |                 |                |                |
| subjects affected / exposed                     | 1 / 18 (5.56%)  | 0 / 6 (0.00%)  | 0 / 27 (0.00%) |
| occurrences (all)                               | 1               | 0              | 0              |
| Aspartate aminotransferase increased            |                 |                |                |

|                                                |                 |               |                |
|------------------------------------------------|-----------------|---------------|----------------|
| subjects affected / exposed                    | 1 / 18 (5.56%)  | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 1               | 0             | 0              |
| Alanine aminotransferase increased             |                 |               |                |
| subjects affected / exposed                    | 2 / 18 (11.11%) | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 2               | 0             | 0              |
| C-reactive protein increased                   |                 |               |                |
| subjects affected / exposed                    | 0 / 18 (0.00%)  | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 0               | 0             | 0              |
| Eosinophil count increased                     |                 |               |                |
| subjects affected / exposed                    | 1 / 18 (5.56%)  | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 1               | 0             | 0              |
| Eosinophil percentage increased                |                 |               |                |
| subjects affected / exposed                    | 1 / 18 (5.56%)  | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 1               | 0             | 0              |
| Haematocrit decreased                          |                 |               |                |
| subjects affected / exposed                    | 1 / 18 (5.56%)  | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 1               | 0             | 0              |
| Haemoglobin decreased                          |                 |               |                |
| subjects affected / exposed                    | 1 / 18 (5.56%)  | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 1               | 0             | 0              |
| High density lipoprotein decreased             |                 |               |                |
| subjects affected / exposed                    | 1 / 18 (5.56%)  | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 1               | 0             | 0              |
| High density lipoprotein increased             |                 |               |                |
| subjects affected / exposed                    | 1 / 18 (5.56%)  | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 1               | 0             | 0              |
| Platelet count increased                       |                 |               |                |
| subjects affected / exposed                    | 1 / 18 (5.56%)  | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 1               | 0             | 0              |
| Protein total decreased                        |                 |               |                |
| subjects affected / exposed                    | 1 / 18 (5.56%)  | 0 / 6 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all)                              | 1               | 0             | 0              |
| Injury, poisoning and procedural complications |                 |               |                |
| Tendon injury                                  |                 |               |                |

|                                                  |                      |                     |                      |
|--------------------------------------------------|----------------------|---------------------|----------------------|
| subjects affected / exposed<br>occurrences (all) | 1 / 18 (5.56%)<br>1  | 0 / 6 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0  |
| Cardiac disorders                                |                      |                     |                      |
| Palpitations                                     |                      |                     |                      |
| subjects affected / exposed<br>occurrences (all) | 1 / 18 (5.56%)<br>1  | 0 / 6 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0  |
| Nervous system disorders                         |                      |                     |                      |
| Dizziness                                        |                      |                     |                      |
| subjects affected / exposed<br>occurrences (all) | 2 / 18 (11.11%)<br>3 | 0 / 6 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0  |
| Headache                                         |                      |                     |                      |
| subjects affected / exposed<br>occurrences (all) | 1 / 18 (5.56%)<br>1  | 0 / 6 (0.00%)<br>0  | 1 / 27 (3.70%)<br>1  |
| Syncope                                          |                      |                     |                      |
| subjects affected / exposed<br>occurrences (all) | 0 / 18 (0.00%)<br>0  | 1 / 6 (16.67%)<br>1 | 0 / 27 (0.00%)<br>0  |
| Paraesthesia                                     |                      |                     |                      |
| subjects affected / exposed<br>occurrences (all) | 1 / 18 (5.56%)<br>1  | 0 / 6 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0  |
| Blood and lymphatic system disorders             |                      |                     |                      |
| Anaemia                                          |                      |                     |                      |
| subjects affected / exposed<br>occurrences (all) | 1 / 18 (5.56%)<br>1  | 0 / 6 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0  |
| Erythropenia                                     |                      |                     |                      |
| subjects affected / exposed<br>occurrences (all) | 1 / 18 (5.56%)<br>1  | 0 / 6 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0  |
| Gastrointestinal disorders                       |                      |                     |                      |
| Abdominal pain                                   |                      |                     |                      |
| subjects affected / exposed<br>occurrences (all) | 0 / 18 (0.00%)<br>0  | 1 / 6 (16.67%)<br>1 | 0 / 27 (0.00%)<br>0  |
| Abdominal pain upper                             |                      |                     |                      |
| subjects affected / exposed<br>occurrences (all) | 0 / 18 (0.00%)<br>0  | 1 / 6 (16.67%)<br>2 | 0 / 27 (0.00%)<br>0  |
| Diarrhoea                                        |                      |                     |                      |
| subjects affected / exposed<br>occurrences (all) | 0 / 18 (0.00%)<br>0  | 1 / 6 (16.67%)<br>1 | 3 / 27 (11.11%)<br>3 |
| Nausea                                           |                      |                     |                      |

|                                        |                 |                |                 |
|----------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed            | 0 / 18 (0.00%)  | 1 / 6 (16.67%) | 0 / 27 (0.00%)  |
| occurrences (all)                      | 0               | 1              | 0               |
| Vomiting                               |                 |                |                 |
| subjects affected / exposed            | 1 / 18 (5.56%)  | 2 / 6 (33.33%) | 1 / 27 (3.70%)  |
| occurrences (all)                      | 1               | 2              | 1               |
| Hepatobiliary disorders                |                 |                |                 |
| Hepatic function abnormal              |                 |                |                 |
| subjects affected / exposed            | 1 / 18 (5.56%)  | 0 / 6 (0.00%)  | 0 / 27 (0.00%)  |
| occurrences (all)                      | 1               | 0              | 0               |
| Skin and subcutaneous tissue disorders |                 |                |                 |
| Alopecia                               |                 |                |                 |
| subjects affected / exposed            | 1 / 18 (5.56%)  | 0 / 6 (0.00%)  | 0 / 27 (0.00%)  |
| occurrences (all)                      | 1               | 0              | 0               |
| Dermatitis allergic                    |                 |                |                 |
| subjects affected / exposed            | 1 / 18 (5.56%)  | 0 / 6 (0.00%)  | 0 / 27 (0.00%)  |
| occurrences (all)                      | 1               | 0              | 0               |
| Erythema                               |                 |                |                 |
| subjects affected / exposed            | 0 / 18 (0.00%)  | 0 / 6 (0.00%)  | 2 / 27 (7.41%)  |
| occurrences (all)                      | 0               | 0              | 2               |
| Pain of skin                           |                 |                |                 |
| subjects affected / exposed            | 1 / 18 (5.56%)  | 0 / 6 (0.00%)  | 0 / 27 (0.00%)  |
| occurrences (all)                      | 1               | 0              | 0               |
| Pustular psoriasis                     |                 |                |                 |
| subjects affected / exposed            | 4 / 18 (22.22%) | 2 / 6 (33.33%) | 5 / 27 (18.52%) |
| occurrences (all)                      | 4               | 2              | 6               |
| Psoriasis                              |                 |                |                 |
| subjects affected / exposed            | 0 / 18 (0.00%)  | 0 / 6 (0.00%)  | 1 / 27 (3.70%)  |
| occurrences (all)                      | 0               | 0              | 1               |
| Pruritus                               |                 |                |                 |
| subjects affected / exposed            | 0 / 18 (0.00%)  | 0 / 6 (0.00%)  | 2 / 27 (7.41%)  |
| occurrences (all)                      | 0               | 0              | 2               |
| Urticaria                              |                 |                |                 |
| subjects affected / exposed            | 1 / 18 (5.56%)  | 1 / 6 (16.67%) | 0 / 27 (0.00%)  |
| occurrences (all)                      | 1               | 1              | 0               |
| Skin erosion                           |                 |                |                 |

|                                                  |                     |                     |                     |
|--------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 18 (0.00%)<br>0 | 1 / 6 (16.67%)<br>1 | 0 / 27 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders  |                     |                     |                     |
| Joint effusion                                   |                     |                     |                     |
| subjects affected / exposed                      | 1 / 18 (5.56%)      | 0 / 6 (0.00%)       | 0 / 27 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                   |
| Bone pain                                        |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 1 / 6 (16.67%)      | 0 / 27 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                   |
| Arthralgia                                       |                     |                     |                     |
| subjects affected / exposed                      | 1 / 18 (5.56%)      | 0 / 6 (0.00%)       | 1 / 27 (3.70%)      |
| occurrences (all)                                | 2                   | 0                   | 1                   |
| Joint swelling                                   |                     |                     |                     |
| subjects affected / exposed                      | 1 / 18 (5.56%)      | 0 / 6 (0.00%)       | 0 / 27 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                   |
| Myalgia                                          |                     |                     |                     |
| subjects affected / exposed                      | 1 / 18 (5.56%)      | 1 / 6 (16.67%)      | 1 / 27 (3.70%)      |
| occurrences (all)                                | 1                   | 1                   | 1                   |
| Oligoarthritis                                   |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 1 / 6 (16.67%)      | 0 / 27 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                   |
| Pain in extremity                                |                     |                     |                     |
| subjects affected / exposed                      | 1 / 18 (5.56%)      | 1 / 6 (16.67%)      | 2 / 27 (7.41%)      |
| occurrences (all)                                | 1                   | 1                   | 2                   |
| Osteoarthritis                                   |                     |                     |                     |
| subjects affected / exposed                      | 1 / 18 (5.56%)      | 0 / 6 (0.00%)       | 0 / 27 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                   |
| Tendonitis                                       |                     |                     |                     |
| subjects affected / exposed                      | 1 / 18 (5.56%)      | 0 / 6 (0.00%)       | 0 / 27 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                   |
| Infections and infestations                      |                     |                     |                     |
| Otitis externa                                   |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 0 / 6 (0.00%)       | 2 / 27 (7.41%)      |
| occurrences (all)                                | 0                   | 0                   | 2                   |
| Pustule                                          |                     |                     |                     |

|                                    |                |                |                |
|------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed        | 0 / 18 (0.00%) | 1 / 6 (16.67%) | 0 / 27 (0.00%) |
| occurrences (all)                  | 0              | 1              | 0              |
| Urinary tract infection            |                |                |                |
| subjects affected / exposed        | 0 / 18 (0.00%) | 1 / 6 (16.67%) | 1 / 27 (3.70%) |
| occurrences (all)                  | 0              | 1              | 1              |
| Streptococcal infection            |                |                |                |
| subjects affected / exposed        | 1 / 18 (5.56%) | 0 / 6 (0.00%)  | 0 / 27 (0.00%) |
| occurrences (all)                  | 1              | 0              | 0              |
| Metabolism and nutrition disorders |                |                |                |
| Hyperuricaemia                     |                |                |                |
| subjects affected / exposed        | 1 / 18 (5.56%) | 0 / 6 (0.00%)  | 0 / 27 (0.00%) |
| occurrences (all)                  | 1              | 0              | 0              |
| Decreased appetite                 |                |                |                |
| subjects affected / exposed        | 1 / 18 (5.56%) | 0 / 6 (0.00%)  | 0 / 27 (0.00%) |
| occurrences (all)                  | 1              | 0              | 0              |

|                                                          |                              |  |  |
|----------------------------------------------------------|------------------------------|--|--|
| <b>Non-serious adverse events</b>                        | Spesolimab 900 mg<br>i.v. SD |  |  |
| Total subjects affected by non-serious<br>adverse events |                              |  |  |
| subjects affected / exposed                              | 23 / 35 (65.71%)             |  |  |
| Vascular disorders                                       |                              |  |  |
| Haemorrhage                                              |                              |  |  |
| subjects affected / exposed                              | 0 / 35 (0.00%)               |  |  |
| occurrences (all)                                        | 0                            |  |  |
| Hypotension                                              |                              |  |  |
| subjects affected / exposed                              | 0 / 35 (0.00%)               |  |  |
| occurrences (all)                                        | 0                            |  |  |
| General disorders and administration<br>site conditions  |                              |  |  |
| Asthenia                                                 |                              |  |  |
| subjects affected / exposed                              | 1 / 35 (2.86%)               |  |  |
| occurrences (all)                                        | 2                            |  |  |
| Fatigue                                                  |                              |  |  |
| subjects affected / exposed                              | 2 / 35 (5.71%)               |  |  |
| occurrences (all)                                        | 2                            |  |  |
| Inflammation                                             |                              |  |  |
| subjects affected / exposed                              | 0 / 35 (0.00%)               |  |  |
| occurrences (all)                                        | 0                            |  |  |



|                                                                                                               |                     |  |  |
|---------------------------------------------------------------------------------------------------------------|---------------------|--|--|
| Oedema peripheral<br>subjects affected / exposed<br>occurrences (all)                                         | 2 / 35 (5.71%)<br>2 |  |  |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)                                                   | 2 / 35 (5.71%)<br>2 |  |  |
| Reproductive system and breast disorders<br>Dysmenorrhoea<br>subjects affected / exposed<br>occurrences (all) | 0 / 35 (0.00%)<br>0 |  |  |
| Hypomenorrhoea<br>subjects affected / exposed<br>occurrences (all)                                            | 0 / 35 (0.00%)<br>0 |  |  |
| Respiratory, thoracic and mediastinal disorders<br>Cough<br>subjects affected / exposed<br>occurrences (all)  | 0 / 35 (0.00%)<br>0 |  |  |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 35 (0.00%)<br>0 |  |  |
| Insomnia<br>subjects affected / exposed<br>occurrences (all)                                                  | 0 / 35 (0.00%)<br>0 |  |  |
| Investigations<br>Blood lactate dehydrogenase increased<br>subjects affected / exposed<br>occurrences (all)   | 0 / 35 (0.00%)<br>0 |  |  |
| Aspartate aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)                      | 1 / 35 (2.86%)<br>1 |  |  |
| Alanine aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)                        | 1 / 35 (2.86%)<br>1 |  |  |
| C-reactive protein increased                                                                                  |                     |  |  |

|                                                |                |  |  |
|------------------------------------------------|----------------|--|--|
| subjects affected / exposed                    | 2 / 35 (5.71%) |  |  |
| occurrences (all)                              | 3              |  |  |
| Eosinophil count increased                     |                |  |  |
| subjects affected / exposed                    | 0 / 35 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Eosinophil percentage increased                |                |  |  |
| subjects affected / exposed                    | 0 / 35 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Haematocrit decreased                          |                |  |  |
| subjects affected / exposed                    | 0 / 35 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Haemoglobin decreased                          |                |  |  |
| subjects affected / exposed                    | 0 / 35 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| High density lipoprotein decreased             |                |  |  |
| subjects affected / exposed                    | 0 / 35 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| High density lipoprotein increased             |                |  |  |
| subjects affected / exposed                    | 0 / 35 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Platelet count increased                       |                |  |  |
| subjects affected / exposed                    | 1 / 35 (2.86%) |  |  |
| occurrences (all)                              | 1              |  |  |
| Protein total decreased                        |                |  |  |
| subjects affected / exposed                    | 0 / 35 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Injury, poisoning and procedural complications |                |  |  |
| Tendon injury                                  |                |  |  |
| subjects affected / exposed                    | 0 / 35 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Cardiac disorders                              |                |  |  |
| Palpitations                                   |                |  |  |
| subjects affected / exposed                    | 0 / 35 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Nervous system disorders                       |                |  |  |

|                                                                          |                      |  |  |
|--------------------------------------------------------------------------|----------------------|--|--|
| Dizziness<br>subjects affected / exposed<br>occurrences (all)            | 0 / 35 (0.00%)<br>0  |  |  |
| Headache<br>subjects affected / exposed<br>occurrences (all)             | 4 / 35 (11.43%)<br>4 |  |  |
| Syncope<br>subjects affected / exposed<br>occurrences (all)              | 0 / 35 (0.00%)<br>0  |  |  |
| Paraesthesia<br>subjects affected / exposed<br>occurrences (all)         | 0 / 35 (0.00%)<br>0  |  |  |
| Blood and lymphatic system disorders                                     |                      |  |  |
| Anaemia<br>subjects affected / exposed<br>occurrences (all)              | 2 / 35 (5.71%)<br>3  |  |  |
| Erythropenia<br>subjects affected / exposed<br>occurrences (all)         | 0 / 35 (0.00%)<br>0  |  |  |
| Gastrointestinal disorders                                               |                      |  |  |
| Abdominal pain<br>subjects affected / exposed<br>occurrences (all)       | 0 / 35 (0.00%)<br>0  |  |  |
| Abdominal pain upper<br>subjects affected / exposed<br>occurrences (all) | 1 / 35 (2.86%)<br>1  |  |  |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)            | 1 / 35 (2.86%)<br>1  |  |  |
| Nausea<br>subjects affected / exposed<br>occurrences (all)               | 3 / 35 (8.57%)<br>4  |  |  |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)             | 2 / 35 (5.71%)<br>2  |  |  |
| Hepatobiliary disorders                                                  |                      |  |  |

|                                                                               |                        |  |  |
|-------------------------------------------------------------------------------|------------------------|--|--|
| Hepatic function abnormal<br>subjects affected / exposed<br>occurrences (all) | 0 / 35 (0.00%)<br>0    |  |  |
| Skin and subcutaneous tissue disorders                                        |                        |  |  |
| Alopecia<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 35 (0.00%)<br>0    |  |  |
| Dermatitis allergic<br>subjects affected / exposed<br>occurrences (all)       | 0 / 35 (0.00%)<br>0    |  |  |
| Erythema<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 35 (0.00%)<br>0    |  |  |
| Pain of skin<br>subjects affected / exposed<br>occurrences (all)              | 0 / 35 (0.00%)<br>0    |  |  |
| Pustular psoriasis<br>subjects affected / exposed<br>occurrences (all)        | 17 / 35 (48.57%)<br>21 |  |  |
| Psoriasis<br>subjects affected / exposed<br>occurrences (all)                 | 2 / 35 (5.71%)<br>2    |  |  |
| Pruritus<br>subjects affected / exposed<br>occurrences (all)                  | 1 / 35 (2.86%)<br>1    |  |  |
| Urticaria<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 35 (2.86%)<br>1    |  |  |
| Skin erosion<br>subjects affected / exposed<br>occurrences (all)              | 0 / 35 (0.00%)<br>0    |  |  |
| Musculoskeletal and connective tissue disorders                               |                        |  |  |
| Joint effusion<br>subjects affected / exposed<br>occurrences (all)            | 0 / 35 (0.00%)<br>0    |  |  |
| Bone pain                                                                     |                        |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 35 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Arthralgia                  |                |  |  |
| subjects affected / exposed | 2 / 35 (5.71%) |  |  |
| occurrences (all)           | 4              |  |  |
| Joint swelling              |                |  |  |
| subjects affected / exposed | 0 / 35 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Myalgia                     |                |  |  |
| subjects affected / exposed | 2 / 35 (5.71%) |  |  |
| occurrences (all)           | 2              |  |  |
| Oligoarthritis              |                |  |  |
| subjects affected / exposed | 0 / 35 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Pain in extremity           |                |  |  |
| subjects affected / exposed | 2 / 35 (5.71%) |  |  |
| occurrences (all)           | 2              |  |  |
| Osteoarthritis              |                |  |  |
| subjects affected / exposed | 0 / 35 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Tendonitis                  |                |  |  |
| subjects affected / exposed | 1 / 35 (2.86%) |  |  |
| occurrences (all)           | 1              |  |  |
| Infections and infestations |                |  |  |
| Otitis externa              |                |  |  |
| subjects affected / exposed | 0 / 35 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Pustule                     |                |  |  |
| subjects affected / exposed | 1 / 35 (2.86%) |  |  |
| occurrences (all)           | 1              |  |  |
| Urinary tract infection     |                |  |  |
| subjects affected / exposed | 1 / 35 (2.86%) |  |  |
| occurrences (all)           | 1              |  |  |
| Streptococcal infection     |                |  |  |
| subjects affected / exposed | 0 / 35 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |

|                                    |                |  |  |
|------------------------------------|----------------|--|--|
| Metabolism and nutrition disorders |                |  |  |
| Hyperuricaemia                     |                |  |  |
| subjects affected / exposed        | 0 / 35 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Decreased appetite                 |                |  |  |
| subjects affected / exposed        | 0 / 35 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date         | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 19 July 2019 | <p>Amendment 1 Part 1:</p> <p>Based on Health Authority recommendation, the sample size was increased from 27 to 51 patients (placebo: 17, spesolimab: 34) to enhance the safety database and to allow a more robust assessment of efficacy and of the benefit-risk ratio.</p> <p>Based on Health Authority recommendation, the former 2 co-primary endpoints were changed into a primary and a key secondary endpoint. The statistical design - model, the null and alternative hypotheses, the statistical methods, and the analyses were updated.</p> <p>The methods for the handling of missing data were updated. For the estimand concept for the primary and secondary endpoints at Weeks 1 and 4, death was removed from the items considered as non-response. The wording for the AE collection and reporting was updated. For the Adverse events of special interest (AESI) "hepatic injury", Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) <math>\geq 10 \times</math> Upper limit of normal (ULN) was added to the definition. The AESI "Infusion reactions including anaphylactic reaction" was renamed to "systemic hypersensitivity including infusion reactions" and to the emergency procedures during or after infusion of spesolimab, "Systemic hypersensitivity" was added to the "Infusion reactions including anaphylactic reaction". The definition of disease worsening and scenarios when escape treatment may have been given were clarified.</p> <p>Exclusion criterion #14 regarding active or latent tuberculosis was updated.</p> <p>Former exclusion criterion #16 regarding previous allergy immunotherapy was removed. Risankizumab was added as restricted medication. The washout period was reduced for all biologics to 2 months. The assessment of fever on dosing days was further specified. As tuberculosis test, T-Spot® was also allowed. The eligibility criteria for the open-label extension trial were updated.</p> |
| 19 July 2019 | <p>Amendment 1 Part 2:</p> <p>For the biomarker and pharmacogenomic analyses, a staged approach was introduced. Healthcare resource utilization (HCRU) data collection throughout the trial was added. Not flaring within the 6-month screening period was added as screening failure. The requirement to assign a new patient number in the case of re-screening was added.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 26 June 2020 | <p>The following main changes were introduced by the amendment:</p> <p>To explore the efficacy and safety of open-label spesolimab i.v. treatment on Day 8 was added as additional objective.</p> <p>A set of further endpoints to explore the efficacy of OL spesolimab on Day 8 and information on their analyses were added. 2 further endpoints were added (change from baseline in GPPGA total score by visit, change from baseline in GPPGA pustulation subscore by visit). Time points for a primary analysis at Week 12 (i.e. including data up to Week 12) and a final analysis, if applicable, were added and the blinding plans for these analyses were updated. A sensitivity analysis for the primary endpoint using logistic regression and an estimand for the analysis of secondary continuous endpoints were added. The methods for the handling of missing data were updated.</p> <p>The wording for the AE collection for patients who continued in the extension trial was updated.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

A large proportion of patients in both arms had been treated as non-responders at Week 4, and the true efficacy outcomes for the randomized treatment at this time-point were never observed for the analysis.

Notes: